Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
======================================================================================================================================================

* Erika J Lampert
* Ashley Cimino-Mathews
* Joo Sang Lee
* Jayakumar Nair
* Min-Jung Lee
* Akira Yuno
* Daniel An
* Jane B Trepel
* Eytan Ruppin
* Jung-Min Lee